.7 % reached clinical remission stable for 6 months. ATIC rs2372536 GG genotype was associated with improved clinical remission (adjusted p value = 0.0090). For ITPA, rs1127354 A variant was associated with reduced clinical remission: (adjusted p value = 0.028); this association was present even for patients with wild-type ITPA and low ITPA activity. These preliminary results indicate that genotyping of ATIC rs2372536 and ITPA rs1127354 variants or measuring ITPA activity could be useful to predict methotrexate response in children with JIA after validation by further prospective studies on a larger patient cohort.
ribonucleotide-transformylase (ATIC) that affects purine synthesis [6] . The latter is the pathway most potently inhibited by methotrexate polyglutamates, which results in a reduced conversion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to formyl-AICAR by the enzyme ATIC [8] . Anti-inflammatory effects of methotrexate are thought to be related to accumulation of adenosine, a potent anti-inflammatory mediator, mainly consequent to ATIC inhibition [9] .
Recent studies have evaluated effects of genetic variants in the complex pathway of candidate genes involved in methotrexate pharmacokinetics and pharmacodynamics on the response to the medication in adults with rheumatoid arthritis and children with JIA [8, 10, 11] . Hinks et al. [8] presented an association of two SNPs in the ATIC gene and one SNP within the inosine-triphosphate-pyrophosphatase (ITPA) gene with reduced response to methotrexate in JIA; only one of the ATIC SNPs showed any trend toward MTX response in an independent cohort of North American JIA children (the ITPA SNP was not genotyped in the validation cohort). Another study by de Rotte et al. [10] identified an association between SLC19A1 rs1051266 and response to methotrexate in 287 patients with JIA studied longitudinally.
Although fine mapping of genetic variants or genomewide studies into MTX response in JIA or RA are lacking [12, 13] and despite inconsistencies in results from reports about MTX pharmacogenetics, published studies indicate that relevant variants to predict methotrexate response in JIA are those in ATIC, ITPA and SLC19A1 genes.
The aim of the present study was, therefore, to evaluate the role of these candidate genetic factors on the response to methotrexate in terms of clinical remission in an Italian cohort of children with JIA.
Materials and methods

Patients and study design
Children who fulfilled International League of Associations for Rheumatology (ILAR) criteria for JIA, and who received methotrexate or were going to start methotrexate for active arthritis, were enrolled at Burlo Garofolo Children's Hospital. Children affected by systemic subtype of JIA were excluded. The study was carried out in compliance with the Helsinki Declaration and had full ethical approval by Burlo Garofolo Ethical Committee. Fully informed parental consent and child assent when appropriate was obtained. Demographic and clinical data were collected at baseline (up to 4 weeks before starting methotrexate) and after 6 months of methotrexate therapy, and then every 3 months during treatment. Methotrexate treatment lasted a minimum of 6 months. Minimum follow-up for each patient was 12 months. Weekly methotrexate was given by either oral or subcutaneous route at 10-15 mg/m 2 . Data allowing assessment of clinical response to the drug were collected using the validated core set variables [14] and the definition of clinical remission on medication for JIA, according to Wallace criteria [15] . To declare achievement of clinical remission, the patient must have not received other medications (NSAID, oral steroids, intraarticular steroids) for a 6-month period of inactive disease on methotrexate [15] . The absolute disease activity at baseline and in follow-up is evaluated with Juvenile Arthritis Disease score (JADAS) [16] .
Venous blood samples were taken when the child required blood sampling for routine clinical care.
SNP selection
A total of three SNPs in three genes in the methotrexate pathway were selected for genotyping, on the basis of results from recent comprehensive studies [8, 9, 17] . In particular, analysis was performed for the coding non-synonymous SNPs rs2372536 in ATIC, rs1127354 in ITPA and rs1051266 in SLC19A1 [18] .
Genotyping
Genomic DNA was extracted from peripheral blood samples using a commercial kit (Sigma, Milan, Italy) and stored at −20 °C until use. Genotyping for rs2372536 in ATIC and rs1127354 in ITPA was carried out using the TaqMan Pre-Developed Assay Reagents for genotyping (assay ID: C_16218146_10 and C_27465000_10, respectively, Applied Biosystems, Foster City, CA, USA), according to the manufacturer instructions. Genotyping of rs1051266 in SLC19A1 was done using a PCR-RFLP assay [19] .
Measurement of ITPA activity
Red cell ITPA activity was measured by evaluation of the hydrolysis of ITP to IMP in lysates of patients' erythrocytes with HPLC, according to the method by Shipkova et al. [20] . The reaction mixture contains ITP and, 15 min after the addition of a fixed amount of lysates, the sample is extracted by addition of perchloric acid, neutralized and loaded on the HPLC for quantification of IMP. ITPA activity is expressed as units (U): 1 U corresponds to 1 µmol IMP/g hemoglobin/h.
Statistical analysis
Statistical analysis was performed using the software R (version 3.0).
Each SNP was tested for conformance of genotype frequencies to those expected under Hardy-Weinberg equilibrium with a chi-square goodness-of-fit test.
Analysis for association of clinical response, evaluated as a categorical variable (i.e., attaining an ACRPed score of at least 70 and clinical remission on methotrexate for a 6-month period), was performed by logistic regression. For these analyses, binomial models were generated using response to methotrexate as the dependent variable and the clinical, demographic or genetic covariate of interest (i.e., gender, age, disease duration at methotrexate start, methotrexate route of administration, methotrexate dose, frequency of homozygous variant genotype for ATIC, ITPA or SLC19A1, ITPA activity) as the independent variable. Odds ratios were calculated from estimates of the logistic regression models; for models with zero counts in a level of the variables, Haldane's modification was used to calculate odds ratio, which add 0.5 to all cells to accommodate for the zero count [21] .
For the analysis considering continuous variables (disease activity as JADAS score, evaluated at the start of methotrexate therapy or after 6 months of treatment and ITPA enzymatic activity), generalized linear models of the Gaussian family were used. Before applying linear models, normality of the continuous variable was assessed by visual examination of the histogram and Shapiro test; if distribution resulted non-normal, Box-Cox transformation was applied to increase normality. Analysis of the effect of genotypes on the difference in JADAS score between 6 months of therapy and at methotrexate start, adjusted for baseline JADAS score, was done by linear models, with JADAS score at 6 months as the dependent variable and the candidate genotype and JADAS score at methotrexate start as the independent variables.
For all statistical test, adjustment for multiple testing was done by calculating adjusted p values with Holm's method.
Results
Patients enrolled
Seventy-three patients with JIA treated with methotrexate were considered. These are all consecutive patients treated with methotrexate at Burlo Garofolo Children's Hospital since 2000. Four patients have been excluded from the study: one with systemic subtype of JIA, two treated with a biologic drug (etanercept) in association with methotrexate and one with incomplete data available. We present, therefore, retrospective results from 69 children whose full core set variable data and DNA sample were available.
Demographic and clinical data are reported in Table 1 . Most patients have been treated with subcutaneous administration (43/69, 62.3 %) of the medication; oral administration has been used in the rest of the cohort (26/69, 37.7 %).
Clinical response
Clinical remission
Clinical remission was achieved by 37.7 % of patients (26/69). Patients' gender, age at disease onset, age at methotrexate start, disease subtype, disease duration, methotrexate administration route and dose did not have a significant effect on response to therapy evaluated as clinical remission (Table 1) .
ACRPed score
The results for each response definition for patients considered are ACRPed30 for 79.7 % (55/69) of patients, ACRPed50 for 73.9 % (51/69) and ACRPed70 for 52.2 % (36/69); 20.3 % (14/69) failed to reach even ACRPed30 score. Note that all children who reach ACRPed70 automatically also reach ACRPed30 and ACRPed50, while those who achieve ACRPed50 also achieve ACRPed30. Patients' gender, age at disease onset, age at methotrexate start, disease subtype, disease duration at methotrexate start, methotrexate administration route and dose did not have a significant effect on response to therapy evaluated as ACRPed score (Supplementary Table 1 ).
JADAS score
Disease activity at the start of treatment with methotrexate, evaluated with the JADAS score, indicated a median value of 18.3 (range 3.0-49.8); after 6 months of treatment with methotrexate, a pronounced reduction in the disease activity was achieved (p value = 3.0 × 10 −16 , linear model), with a median value of 5.3 (range 0-36.8).
Genotyping
SNPs genotyped in this cohort, rs2372536 in ATIC, rs1127354 in ITPA and rs1051266 in SLC19A1 were characterized in all patients (69/69). All polymorphisms considered follow Hardy-Weinberg equilibrium, and their frequency is in agreement with the distribution of these SNPs in the Caucasian population, with minor allele frequency of 37.7, 4.3 and 49.3 %, respectively, for ATIC rs2372536 (C>G), ITPA rs1127354 (C>A) and SLC19A1 rs1051266 (A>G).
Clinical response and genotyping
Clinical remission
Considering clinical remission, results for significant associations are shown in Table 2 . ATIC rs2372536 presented a significant effect (p value adjusted for multiple testing 0.0090, logistic regression): homozygous variant G genotype was more frequent in patients achieving clinical remission (31 % in patients with clinical remission vs 5 % in patients with no clinical remission, odds ratio 9.11, 95 % CI 1.76-47.23). ITPA rs1127354 also presented a significant 
ACRPed scores
Trends for an association with improved response evaluated as ACRPed70score, evaluated at 6 months, were identified for SLC19A1 rs1051266 and ATIC rs2372536; however, these tendencies were not significant after adjusting for multiple testing (Table 3) . No significant effect was identified for the variant in ITPA on response to methotrexate in terms of ACRPed70 score (Table 3) .
JADAS scores
Considering disease activity evaluated by JADAS score at the start of treatment with methotrexate and after 6 months of therapy, SLC19A1 rs1051266 SNP demonstrated statistically significant effects (Fig. 1) . Patients with a variant GG genotype for SLC19A1 rs1051266 presented higher JADAS scores after 6 months of therapy in comparison with patients with either AA or AG genotypes (p value adjusted for multiple testing = 0.012, linear model). SLC19A1 rs1051266 had no significant effect on JADAS score at the beginning of methotrexate therapy. Analysis of the JADAS score after 6 months of therapy, adjusted for baseline JADAS score, showed that both baseline JADAS score and SLC19A1 values are from linear models. Adjustment for multiple comparison was done using Holm's method genotype had a significant association with JADAS score after 6 months of therapy ( Fig. 1, p value adjusted for multiple testing, respectively, <0.0001 and 0.036, linear models). No significant effect of the ATIC and ITPA SNPs considered on JADAS score was identified ( Supplementary  Figures 1, 2) .
ITPA activity
ITPA activity was measured successfully in erythrocytes from 62/73 patients. As expected, a highly significant association of the enzymatic activity with SNP rs1127354 in ITPA was detected, so that the variant A allele additively induced a reduction in the enzyme activity: indeed, ITPA activity was 162.7, 52.4 and 0.75 U among patients with CC, CA and AA genotype, respectively (Fig. 2 , p value = 1.0 × 10 −5 , linear model). ITPA activity was not associated with patients' gender, age, disease subtype. Moreover, no association of ITPA activity was detected with methotrexate dose or clinical response to methotrexate, measured either with ACRPed score or as clinical remission. However, all nine patients with low ITPA activity (<92 U, highest value observed in patients with variant ITPA genotype) did not achieve clinical remission, while frequency of remission was 43.4 % (23/53) among patients with ITPA activity higher than 92 U ( Table 4 , p value = 0.0024, logistic regression).
Discussion
Polymorphisms in genes encoding for enzymes involved in methotrexate pharmacokinetics and pharmacodynamics have been associated with drug response. Recent studies have evaluated the effect of various candidate variants in adults with rheumatoid arthritis and children with JIA [8, 10, 17, 18] . Hinks et al. [8] have characterized genetic variability in 13 candidate genes involved in methotrexate pharmacokinetic and pharmacodynamic pathways, using for each gene the tagSNPs, selected on the basis of the haplotype map. This study considered two large cohorts of patients with JIA, one from UK and one from USA. Results obtained have shown that two SNPs in the ATIC gene and one SNP within ITPA were significantly associated with methotrexate response in the discovery cohort from UK. One of the SNPs in ATIC, an intronic variant (rs12995526), showed a trend with association even in the validation cohort from USA. Another study by de Rotte et al. [10] identified an association between SLC19A1 rs1051266 and response to methotrexate in 287 patients with JIA studied longitudinally. Moreover, two recent studies in adult patients with rheumatoid arthritis have used a similar approach [17, 18] . On these bases, we studied the effects of the main functional variant of ATIC, ITPA and SLC19A1 (respectively, rs2372536, rs1127354 and rs1051266) on response to methotrexate in a cohort of Italian patients with JIA. ATIC and ITPA are two genes encoding enzymes involved in purines biosynthesis and metabolism, while SLC19A1 is a transporter responsible for methotrexate influx in cells [6] . Our study considered a cohort of 69 patients, which constitutes all consecutive patients with JIA that have been treated with methotrexate at Burlo Garofolo Children's Hospital between 2000 and 2013.
Results show that frequency of response to methotrexate evaluated in this study is similar to that reported in the literature [1, 22] . As expected, the majority of patients enrolled are females; however, demographic, clinical and pharmacological covariates had no significant effects on response to therapy. In particular, route of methotrexate administration had no significant effect on response to the medication; this observation is in agreement with recent reports [10, 23] . As far as the effect of the candidate genotypes considered is concerned, our study showed a significant effect of the functional variant in ATIC (rs2372536): variant GG genotype was associated with better response in terms of clinical remission (odds ratio 9.1), with trends for an effect on ACRPed70 (Table 2) and ACRPed30 scores (Supplementary Table 2 ). Even the functional variant in ITPA (rs1127354) presented an effect on response to methotrexate: variant A allele had a lower percentage of clinical remission in comparison with wild-type C allele. Multivariate analysis supported the view that the significant effects of ATIC and ITPA variants on clinical remission were independent. Genetic polymorphisms of ATIC and ITPA may impact MTX response independently since these enzymes are involved in different, though interconnected, enzymatic pathways in cells (i.e., de novo synthesis and salvage pathways for purines, respectively) [18] .
Previous reports in the literature investigated the pharmacogenetics of methotrexate in JIA [8, 10, 11, 24] . Our study is in agreement with previous studies that consider efficacy of methotrexate in patients with rheumatoid arthritis, indicating therefore that the ATIC rs2372536 GG genotype may be associated with improved response even in children with JIA [9, 17, 25] . This variant likely influences methotrexate efficacy since it predisposes the ATIC enzyme to the inhibition induced by the methotrexate active metabolites [26] , which results in a more pronounced reduction of de novo purine synthesis and increased adenosine release, the main molecular mechanisms underlying methotrexate efficacy in JIA [9] .
A recent study by de Rotte et al. [10] identified an association between SLC19A1 rs1051266 and response to methotrexate in 287 patients with JIA studied longitudinally. In our study, the SLC19A1 variant rs1051266 was not associated with response to methotrexate evaluated as clinical remission. However, a trend was present for ACRPed70 score (not significant after adjustment for multiple testing as in the study by de Rotte et al.); this observation is in agreement with many other studies reported in the literature, describing a controversial association of this variant with response to methotrexate in JIA and rheumatoid arthritis [8, 19, [27] [28] [29] [30] [31] . Interestingly, in our patients' population, there seem to be an association of this SNP with the change in JADAS scores between methotrexate start and after 6 months of therapy: patients homozygous for the variant GG genotype displayed a reduced improvement in JADAS score, in comparison with patients with either AA or AG genotype. However, this effect was not associated with modifications of the clinical remission rate. This is the first report about an effect of SCL19A1 rs1051266 genotype on JADAS score change and should be validated by other studies; moreover, clinical relevance of this observation may be limited, since this effect did not modify clinical remission induced by methotrexate [15] .
Distribution of ITPA activity measured in erythrocytes of JIA patients enrolled in this study and its association with ITPA rs1127354 variant are consistent with previous reports in healthy subjects [20, 32] . To note, especially for the rs1127354 CC genotype, there is a large amount of variation in levels of enzymatic activity between individuals. This observation is consistent with previous reports in the literature [20] and may be related to the effect of genetic polymorphisms in genes different from ITPA on its enzymatic activity ("trans effect"), as it has been shown recently for TPMT [33] . Although average ITPA activity was not different between responders and non responders, low activity of ITPA measured in erythrocytes was associated with reduced methotrexate response in this study, confirming the role of ITPA rs1127354 variant; indeed even patients with normal ITPA genotype and low ITPA activity, comparable to that measured in patients with variant ITPA, did not respond to therapy. This observation and the role of ITPA activity on methotrexate response need to be further evaluated by larger prospective studies, possibly considering even ITPA gene expression [13, 34] . This is the first report considering the pharmacogenetics of response to methotrexate in JIA in terms of clinical remission. This clinical phenotype may be more relevant to describe the benefit induced by the treatment and to guide patient care, in comparison with the ACRPed score or changes in JADAS score, since it represents a longer period in which the patient does not present signs of disease activity, including uveitis, the most significant complication of JIA [15] .
Identification of patients who are likely to respond to methotrexate before treatment in JIA would be very useful for the clinician, and our study supports the development of multilocus pharmacogenetic signatures to predict response to methotrexate in these patients. Genotyping should be performed at diagnosis and patients with a genotype predisposing to response, such as the ATIC rs2372536 GG genotype, should be treated with methotrexate, given the high probability of response to this treatment. This study provides a rational for reserving biologics to patients that will likely not benefit from less expensive but still effective treatments such as methotrexate. On the contrary, patients with variants associated with lack of efficacy of methotrexate (such as ITPA rs1127354 A allele and in general those with low ITPA activity), should be switched more rapidly to a more aggressive treatment (i.e., methotrexate + biologics or biologics alone). Methotrexate remains, however, the first-line treatment in children with JIA requiring DMARDs.
We acknowledge that the associations described in this study about explored genetic variants and different indicators of clinical response are heterogeneous: this is likely secondary to the relatively small number of patients recruited. The results, therefore, have to be interpreted as preliminary and need further confirmatory studies on larger cohort of patients.
A key limitation of this study is the lack of a validation cohort supporting its findings, limiting at this point the extensibility of this observation to the general population. Moreover, given the paucity of studies that comprehensively fine mapped candidate genes to identify the causal variants in each or genome-wide association studies into MTX response in JIA or RA, it is possible that additional genetic effects will be contained within other genomic regions not yet investigated [12] . If the results described in the present study will be validated by larger prospective trials, application of pharmacogenetic guided treatment of JIA may allow rationalization and reduction of costs associated with care, by directing and personalizing the use of methotrexate and biologics.
